A Study of IBI362 in Participants With Obesity or Overweight
Status:
Not yet recruiting
Trial end date:
2024-04-14
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study
evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will
be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle
includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week
drug withdrawal follow-up period after the end of treatment.